Evaluating DNTH103 for treating chronic inflammatory demyelinating polyneuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 study aims to assess the efficacy and safety of DNTH103 in adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). The trial consists of an open-label period followed by a randomized, placebo-controlled phase for participants who respond positively to DNTH103. An optional open-label extension is available for eligible participants, allowing for continued treatment and monitoring. The study will also include a safety follow-up period to evaluate long-term effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must have given written informed consent before any study-related activities are carried out.
2. Weight range between 40 kilograms (kg) and 120 kg.
3. Confirmed diagnosis of CIDP or possible CIDP. Participants must have either typical CIDP or one of the following variants: motor or multifocal CIDP. Diagnosis must be confirmed by the Independent CIDP Review Panel.
4. CIDP Disease Activity Status (CDAS) score ≥ 3 at screening.
5. Must be neurologically stable.
6. Must have an INCAT score between 2 and 9 inclusive.
7. Must fulfill one of the following treatment conditions for CIDP:

   1. Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin \[IVIg\] or subcutaneous immunoglobulin \[SCIg\]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids.
   2. Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.
   3. Refractory participants who have had treatment failure (worsening) or an inadequate response to Ig and/or oral corticosteroids (defined as no clinically meaningful improvement after a period of a minimum of 12 weeks, which may include both active treatment and observation to assess response), or who at any time were unable to tolerate these treatments, experienced adverse effects, or have documented contraindications.
   4. Treatment naïve with no history of prior treatment for CIDP.
8. Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.
9. Female participants must be of nonchildbearing potential or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception.
10. Male participants must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception or be surgically sterile for at least 90 days prior to Screening.

Exclusion Criteria:

1. Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP.
2. Known evidence of central demyelination or known history of myelopathy.
3. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could have a potential impact on safety/efficacy or study procedures.
4. Any other condition, including mental illness or prior therapy that would make the participant unsuitable for this study.
5. Known complement deficiency or history of positive titer for anti-C1 antibodies.
6. Diagnosis of systemic lupus erythematosus (SLE) or family history of SLE (defined as a parent, sibling, or child).
7. Participants with an autoimmune disease affecting joints, muscle or nervous system.
8. Any coexisting or overlapping condition, which may interfere with outcome assessments, such as severe diabetic neuropathy, fibromyalgia, inflammatory arthritis or osteoarthritis affecting the hands and feet.
9. Prior history of N. meningitidis infection.
10. History of active malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.
11. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.

Where it's running

• Clinical Study Site
  Birmingham, Alabama, United States Recruiting
• Clinical Study Site
  Phoenix, Arizona, United States Recruiting
• Clinical Study Site
  Scottsdale, Arizona, United States Recruiting
• Clinical Study Site
  Los Angeles, California, United States Recruiting
• Clinical Study Site
  San Francisco, California, United States Recruiting
• Clinical Study Site
  San Francisco, California, United States Recruiting

+151 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Dianthus Clinical Contact Center
• Email: clinicaltrials@dianthustx.com
• Phone: 929-999-4055

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy

  This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT07154524

• Empasiprubart for adults with CIDP

  This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.

  Recruiting at 94 sites Phase 3 argenx · Birmingham, Alabama and 93 other locations · NCT07091630

• Imeroprubart for adults with CIDP

  This study will test whether the monoclonal antibody Imeroprubart helps adults with active CIDP who are already on stable immunoglobulin or corticosteroid treatment.

  Recruiting at 117 sites Phase 2 Immunovant Sciences GmbH · Tucson, Arizona and 141 other locations · NCT07032662

• Empasiprubart versus IVIg for treating CIDP in adults

  This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.

  Recruiting at 107 sites Phase 3 argenx · Birmingham, Alabama and 106 other locations · NCT06920004

• KIg10 (intravenous human immune globulin 10%) maintenance therapy for CIDP

  This trial will test whether two different maintenance doses of IV immune globulin (KIg10), given every three weeks, help adults with CIDP stay stable and avoid worsening.

  Recruiting at 6 sites Phase 3 Kedrion S.p.A. · Stamford, Connecticut and 5 other locations · NCT06752356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.